2022-24 Mpox (Monkeypox) Outbreak:
Global Trends

World Health Organization

Produced on 22 August 2024

logo

Key figures

WHO African Region

Data as updated weekly; from 01 January 2022 to 18 August 2024

Total cases

5 940

Total deaths

48

Countries reporting cases

15

Total cases in 2024

3 562

Total deaths in 2024

26

Countries reporting cases in 2024

12

Global

Data as updated monthly; from 01 January 2022 to 31 July 2024

Total cases

102 997

Total deaths

223

Countries reporting cases

121

Total cases in July 2024

1 425

Total deaths in July 2024

6

Countries reporting cases in July 2024

35

1 Overview

This report provides an overview of the mpox epidemiological situation in the WHO African Region, on a weekly basis (as of August 2024), as well as the global epidemiological situation on a monthly basis (as of July 2024).

On 14 August 2024, under the International Health Regulations (2005), the WHO Director General declared that the increase in mpox cases in the Democratic Republic of the Congo and its expansion to neighboring countries constitutes a Public Health Emergency of International Concern (PHEIC). This spread presents a public health risk to other Member States and requires a coordinated international response.

The spread of cases in the Democratic Republic of Congo is attributed to two distinct outbreaks - spread of monkeypox virus (MPXV) clade Ia in Equateur and endemic regions of the country, and the emergence of a new MPXV clade (clade Ib) in the South and North Kivu provinces.

WHO conducted the latest global mpox risk assessment in August 2024. Based on the available information, the mpox risk was assessed as follows:

  • In Eastern Democratic Republic of the Congo and neighbouring countries, the overall risk is assessed as high.
  • In areas of the Democratic Republic of the Congo where mpox is endemic, mpox risk is assessed as high.
  • In Nigeria and countries of West, Central and East Africa where mpox is endemic, mpox risk is assessed as moderate.
  • In all other countries in Africa and around the world, the risk is assessed as moderate.

This report mainly focuses laboratory confirmed case and deathss2 as defined by the WHO’s working case definition published in the Surveillance, case investigation and contact tracing for monkeypox interim guidance. Note that countries3,4 may use their own case definitions separate from those outlined in the above document.

Please note that regardless of geographic area, epidemiological context, biological sex, gender identity or sexual orientation, individual-level risk is largely dependent on individual factors such as exposure risk and immune status.

This report should be considered in the context of other WHO information products associated with the 2022-24 mpox outbreak, and mpox in general. Links to these products can be found at the end of the report.

 


  1. On of 28 November 2022, WHO recommended using the name mpox as a new name for monkeypox. The words were used synonymously for one year as the term monkeypox was phased out.

  2. For the WHO European region, both confirmed and probable cases are included within confirmed case counts and detailed case data.

  3. Throughout this document, any use of the word country should be considered shorthand for a country, area, or territory


2 WHO African Region situation

logo

This section of the report is jointly authored by the WHO Regional Office for Africa and WHO Headquarters.

Since 1 January 2022, cases of mpox have been reported to WHO from 15 Member States across the African Region. As of 18 August 2024 , a total of 5 940 laboratory confirmed cases, including 48 deaths, have been reported to WHO.

In 2024, as of 18 August 2024, 12 countries have reported 3 562 confirmed cases, including 26 deaths. The three countries with the majority of the cases in 2024 are Democratic Republic of the Congo, (n = 3 235), Burundi, (n = 153), and Central African Republic, (n = 45).

A significant number of suspected cases, that are clinically compatible with mpox are not tested due to limited diagnostic capacity and get never confirmed. Work on integrating this data is currently ongoing and will be included in future updates of this report.

2.1 Clade Ia, Ib, and II presence

As of 18 August 2024, the distribution of reported mpox clades around the African Region is shown in the map below. It should be noted that in many cases, sequencing may not capture all circulating clades, leading to underreporting of where clades are circulating.

This map can be clicked to view on a larger scale

2.2 Epidemic curves

Epidemic curve shown by week for laboratory confirmed cases reported up to 18 Aug 2024. Note that for the purposes of these epidemic curves, countries with more than one clade present are presented in multiple epidemic curves. The most recent weeks presented in the epidemic curves should be interpreted with caution, as there are delays associated with reporting.

2.2.1 All African Region countries

2.2.2 Clade Ib countries

2.2.3 Clade Ia countries

2.2.4 Clade II countries


2.3 Maps

Note: Maps can be clicked to view on a larger scale. Note that data are only shown for the WHO African region - data from other regions are reflected in the global sections of the report.

2.3.1 Cumulative cases

2.3.2 Cases in 2024

2.3.3 Cumulative deaths

2.3.4 Deaths in 2024


2.4 Data by country

Summary of Mpox cases
As of 18 Aug 2024
Country Total cases Total deaths Case fatality ratio (%) Cases in 20241 Deaths in 20241 Cases in the past two weeks2 Deaths in the past two weeks2 Clades detected in country Date of last report
Democratic Republic of the Congo 4,480 21 0% 3,235 19 38 0 Clades Ia and Ib 11 August 2024
Nigeria 901 9 1% 40 0 2 0 Clade II 18 August 2024
Burundi 153 0 0% 153 0 113 0 Clade Ib 18 August 2024
Ghana 127 4 3% 0 0 0 0 Clade II 18 August 2024
Central African Republic 92 2 2% 45 1 2 0 Clade Ia 18 August 2024
Cameroon 50 5 10% 5 2 0 0 Clades Ia and II 18 August 2024
Congo 45 2 4% 19 0 0 0 Clade Ia 18 August 2024
South Africa 29 3 10% 24 3 0 0 Clade II 18 August 2024
Côte d’Ivoire 28 1 4% 28 1 22 1 Clade II 18 August 2024
Liberia 23 0 0% 5 0 0 0 Clade II 18 August 2024
Rwanda 4 0 0% 4 0 0 0 Clade Ib 18 August 2024
Benin 3 0 0% 0 0 0 0 Clade II 18 August 2024
Uganda 3 0 0% 3 0 1 0 Clade Ib 18 August 2024
Kenya 1 0 0% 1 0 0 0 Clade Ib 18 August 2024
Mozambique 1 1 100% 0 0 0 0 Clade II 18 August 2024
1 From 01 Jan 2024 to 18 Aug 2024
2 From 05 Aug 2024 to 18 Aug 2024

2.5 Epidemic curves by country

Epidemic curve shown by week for cases reported up to 18 Aug 2024.

Benin

Burundi

Cameroon

Central African Republic

Congo

Côte d’Ivoire

Democratic Republic of the Congo

Ghana

Kenya

Liberia

Mozambique

Nigeria

Rwanda

South Africa

Uganda

Data by country can be downloaded as a csv file by clicking the button below. The data includes the number of new cases and deaths reported each week, as well as the total number of cases and deaths reported to date. The data is current as of 18 Aug 2024.

 




3 Global situation update

All of the following data in this report is presented in the context of the ongoing global mpox outbreak. The data presented here are based on the most recent data reported to WHO as of 31 July 2024.

Since 1 January 2022, cases of mpox have been reported to WHO from 121 Member States across all 6 WHO regions. As of 31 July 2024 , a total of 102 997 laboratory confirmed cases and 186 probable cases, including 223 deaths, have been reported to WHO.

As of July 2024, the number of monthly reported new cases has increased by 8.8%, compared to the previous month. The majority of cases reported in the past month were notified from the African Region (54.9%) and the Region of the Americas (24.2%).

The 10 most affected countries globally since 1 January 2022 are: United States of America (n = 33 556), Brazil (n = 11 841), Spain (n = 8 104), Democratic Republic of the Congo (n = 4 385), France (n = 4 283), Colombia (n = 4 256), Mexico (n = 4 132), The United Kingdom (n = 4 018), Peru (n = 3 939), and Germany (n = 3 886). Together, these countries account for 80.0% of the cases reported globally.

In the most recent month of reporting, 22 countries reported an increase in the monthly number of cases. In the past month, 35 countries have reported cases.

No countries reported their first case in the past month

With the exception of countries3,4 in West and Central Africa, amongst those countries for whom mpox cases’ exposures have been reported, the ongoing outbreak of mpox continues to primarily affect men who have sex with men (MSM). At present there is no signal suggesting sustained transmission beyond these networks. Confirmation of one case of mpox, in a country, is considered an outbreak.

Global aggregated data are collected through direct reporting from Member States to WHO and its partners or from official country sources. The below epidemic curve shows the aggregated number of cases by month according to the date of case reporting.

3.1 Epidemic curves

3.1.1 Global (cases)

Epidemic curve shown by month for cases reported up to 31 Jul 2024 to avoid showing incomplete months of data.

3.1.2 Global (deaths)

Epidemic curve shown by month for deaths reported up to 31 Jul 2024 to avoid showing incomplete months of data.

3.1.3 By WHO Region (cases)

Epidemic curve shown by month for cases reported up to 31 Jul 2024 to avoid showing incomplete months of data. Note different y-axis scales.

3.1.4 By WHO Region (deaths)

Epidemic curve shown by month for deaths reported up to 31 Jul 2024 to avoid showing incomplete months of data. Note different y-axis scales.

3.1.5 Top 10 countries (cases)

Epidemic curve shown by month for cases reported up to 31 Jul 2024 to avoid showing incomplete months of data. Note different y-axis scales.

3.1.6 By country

Andorra

Argentina

Aruba

Australia

Austria

Bahamas

Bahrain

Barbados

Belgium

Benin

Bermuda

Bolivia (Plurinational State of)

Bosnia and Herzegovina

Brazil

Bulgaria

Burundi

Cambodia

Cameroon

Canada

Central African Republic

Chile

China

Colombia

Congo

Costa Rica

Croatia

Cuba

Curaçao

Cyprus

Czechia

Côte d’Ivoire

Democratic Republic of the Congo

Denmark

Dominican Republic

Ecuador

Egypt

El Salvador

Estonia

Finland

France

Georgia

Germany

Ghana

Gibraltar

Greece

Greenland

Guadeloupe

Guam

Guatemala

Guyana

Honduras

Hungary

Iceland

India

Indonesia

Iran (Islamic Republic of)

Ireland

Israel

Italy

Jamaica

Japan

Jordan

Kenya

Lao People’s Democratic Republic

Latvia

Lebanon

Liberia

Lithuania

Luxembourg

Malaysia

Malta

Martinique

Mexico

Monaco

Montenegro

Morocco

Mozambique

Nepal

Netherlands

New Caledonia

New Zealand

Nigeria

Norway

Oman

Pakistan

Panama

Paraguay

Peru

Philippines

Poland

Portugal

Qatar

Republic of Korea

Republic of Moldova

Romania

Russian Federation

Rwanda

Saint Martin

San Marino

Saudi Arabia

Serbia

Singapore

Slovakia

Slovenia

South Africa

Spain

Sri Lanka

Sudan

Sweden

Switzerland

Thailand

The United Kingdom

Trinidad and Tobago

Türkiye

Uganda

Ukraine

United Arab Emirates

United States of America

Uruguay

Venezuela (Bolivarian Republic of)

Viet Nam

3.3 Maps

Note: Maps can be clicked to view on a larger scale

3.3.1 Cumulative cases

3.3.2 Cumulative deaths

3.3.3 Cases in the past month

3.3.4 Monthly change in cases

3.4 Tables

3.4.1 Cumulative cases and deaths by WHO Region

Total mpox cases, by WHO region
Data as of July 2024
WHO Region Total cases1 Total deaths1 Cases in Jun 2024 Cases in Jul 2024 Monthly % change in cases Month most recent cases reported
Region of the Americas 64,185 144 290 345 19.0% Jul 2024
European Region 27,680 10 100 151 51.0% Jul 2024
African Region 5,665 47 771 782 1.4% Jul 2024
Western Pacific Region 3,665 10 132 123 −6.8% Jul 2024
South-East Asia Region 940 11 11 15 36.0% Jul 2024
Eastern Mediterranean Region 862 1 6 9 50.0% Jul 2024
1 From Jan 2022


3.4.2 Cumulative cases and deaths by country

Total Mpox cases, by WHO region
From 1 Jan 2022. Data as of 31 Jul 2024
Total Confirmed Cases Total Probable Cases Total Deaths
Region of the Americas
United States of America 33,556 0 60
Brazil 11,841 0 15
Colombia 4,256 0 0
Mexico 4,132 0 34
Peru 3,939 0 21
Canada1 1,577 77 0
Chile 1,449 95 4
Argentina 1,154 0 2
Ecuador 728 0 3
Guatemala 405 7 1
Bolivia (Plurinational State of) 265 0 0
Panama 245 0 1
Costa Rica 226 0 1
Paraguay 126 0 0
El Salvador 104 0 0
Dominican Republic 52 2 0
Honduras 44 0 1
Jamaica 21 0 0
Uruguay 19 0 0
Venezuela (Bolivarian Republic of) 12 1 0
Cuba 8 0 1
Martinique 7 0 0
Trinidad and Tobago 4 0 0
Bahamas 3 0 0
Curaçao 3 2 0
Aruba 3 2 0
Guyana 2 0 0
Saint Martin 1 0 0
Barbados 1 0 0
Bermuda 1 0 0
Guadeloupe 1 0 0
European Region
Spain 8,104 0 3
France 4,283 0 0
The United Kingdom 4,018 0 0
Germany 3,886 0 0
Netherlands 1,308 0 0
Portugal 1,196 0 3
Italy 1,056 0 0
Belgium 811 0 2
Switzerland 579 0 0
Austria 348 0 1
Israel 317 0 0
Sweden 300 0 0
Ireland 249 0 0
Poland 223 0 0
Denmark 203 0 0
Norway 107 0 0
Greece 99 0 0
Hungary 85 0 0
Czechia 82 0 1
Luxembourg 61 0 0
Slovenia 47 0 0
Romania 47 0 0
Finland 43 0 0
Serbia 40 0 0
Malta 35 0 0
Croatia 34 0 0
Iceland 17 0 0
Slovakia 16 0 0
Türkiye 12 0 0
Estonia 11 0 0
Bosnia and Herzegovina 9 0 0
Bulgaria 7 0 0
Latvia 6 0 0
Gibraltar 6 0 0
Cyprus 5 0 0
Lithuania 5 0 0
Ukraine 5 0 0
Russian Federation 4 0 0
Andorra 4 0 0
Monaco 3 0 0
Georgia 2 0 0
Greenland 2 0 0
Montenegro 2 0 0
Republic of Moldova 2 0 0
San Marino 1 0 0
African Region
Democratic Republic of the Congo 4,385 0 21
Nigeria 899 0 9
Ghana 127 0 4
Central African Republic 88 0 2
Cameroon 50 0 5
Congo 45 0 2
South Africa 27 0 3
Liberia 23 0 0
Burundi 9 0 0
Côte d’Ivoire 3 0 0
Benin 3 0 0
Rwanda 2 0 0
Uganda 2 0 0
Kenya 1 0 0
Mozambique 1 0 1
Western Pacific Region
China2 2,528 0 1
Australia 379 0 0
Japan 247 0 1
Viet Nam 202 0 8
Republic of Korea 161 0 0
Singapore 61 0 0
New Zealand 53 0 0
Cambodia 13 0 0
Malaysia 9 0 0
Philippines 9 0 0
Guam 1 0 0
New Caledonia 1 0 0
Lao People's Democratic Republic 1 0 0
South-East Asia Region
Thailand 820 0 10
Indonesia 88 0 0
India 27 0 1
Sri Lanka 4 0 0
Nepal 1 0 0
Eastern Mediterranean Region
Saudi Arabia 763 0 0
United Arab Emirates 28 0 0
Lebanon 27 0 0
Sudan 19 0 1
Pakistan 7 0 0
Qatar 5 0 0
Morocco 3 0 0
Egypt 3 0 0
Oman 3 0 0
Bahrain 2 0 0
Iran (Islamic Republic of) 1 0 0
Jordan 1 0 0
-
Total 102,997 186 223
1 Date information is unavailable for 45 cases in Canada
2 Cases shown include those in mainland China (1569), Hong Kong SAR (89), Taipei (868), and Macao (2)


3.4.9 Countries reporting cases in the previous month

Countries reporting cases in July
Country New cases New deaths
African Region
Democratic Republic of the Congo 738 5
Central African Republic 17 1
Burundi 9 0
South Africa 6 0
Nigeria 4 0
Côte d’Ivoire 3 0
Rwanda 2 0
Uganda 2 0
Kenya 1 0
Region of the Americas
United States of America 200 0
Brazil 100 0
Canada 14 0
Peru 13 0
Mexico 7 0
Colombia 6 0
Argentina 5 0
Western Pacific Region
Australia 101 0
China 17 0
New Zealand 2 0
Republic of Korea 2 0
Singapore 1 0
European Region
The United Kingdom 66 0
Germany 29 0
Spain 20 0
France 11 0
Italy 7 0
Denmark 5 0
Netherlands 4 0
Israel 3 0
Portugal 3 0
Belgium 1 0
Norway 1 0
Sweden 1 0
South-East Asia Region
Thailand 15 0
Eastern Mediterranean Region
Saudi Arabia 9 0





4 Detailed case data

Detailed case data are acquired via direct reporting of case-based data from Member States to WHO. Data from cases are reported1 according to the WHO minimum dataset under the International Health Regulations (IHR 2005) Article 6. Completeness of records is variable, meaning denominators for variables may be different from one another. All of the following is derived from detailed case data, and as a result, overall numbers may not be reflective of figures shown with aggregate case numbers. All detailed cases shown are confirmed cases, where the reporting date occurred after 01 January 2022.


  1. Note that a small number of detailed case reports are constructed from official public reports about individual cases.

4.1 Reporting coverage

The detailed case dataset was last updated on July 2024. As of this date, the total number of detailed confirmed cases reported is 93 717, representing 91.0% of all aggregated cases reported.

The table below indicates the reporting coverage between reported aggregated confirmed cases and detailed confirmed cases by countries and per region.

4.1.1 Table - Coverage by region

Mpox reporting completeness
As of 31 Jul 2024
Total Confirmed Cases Total Detailed Confirmed Cases1 % Detailed Cases reported
Region of the Americas 64,185 60,783 94.7%
European Region 27,680 27,550 99.5%
African Region 5,665 672 11.9%
Western Pacific Region 3,665 3,712 101.3%
South-East Asia Region 940 918 97.7%
Eastern Mediterranean Region 862 82 9.5%
1 Note that in rare cases total detailed cases may exceed total confirmed cases due to ongoing data cleaning issues



4.3 Case profile (overall)

As shown below, and stated previously, the ongoing outbreak is largely occurring in networks of men who have sex with men. Note that reported sexual behaviour does not necessarily reflect who the case has had recent sexual history with nor does it imply sexual activity. Generally, severity has been low, with few reported hospitalizations and deaths:

Key features of these cases are as follows:

  • 96.4% (87 558/90 785) of cases with available data are male, the median age is 34 years (IQR: 29 - 41).

  • Males between 18-44 years old continue to be disproportionately affected by this outbreak as they account for 79.4% of reported cases.

  • Of all cases with available data, 3.6% (3 227/90 785) are female:

    • The majority of these cases are reported from the Region of the Americas (2 401/3 227; 74%) and the European Region (450/3 227; 14%)

    • The most commonly reported form of transmission is via sexual encounters (269/523; 51%)

  • Of the 93 217 cases where age was available, there were 1 161 (1.2%) cases reported aged 0-17, out of which 334 (0.4%) were aged 0-4:

    • The majority of cases aged 0-17 are reported from the Region of the Americas (709 /1 161; 61%).
  • 60 cases were reported to be pregnant or recently pregnant. Of these:

    • 5, 12, and 10 cases were in their first, second, and third trimesters respectively. 33 were in an unknown trimester, and 0 were six weeks or less post-partum.

    • The median age was 27.5 years old (IQR: 22.75 - 31).

    • 15 of these cases were known to be hospitalized. 0 were known to be admitted to ICU and 0 were known to have died.

    • The most common mode of transmission was sexual encounter (4/8 cases where route was known).

  • Among cases with known data on sexual behaviour, 85.8% (30 559/35 598) identified as men who have sex with men.

  • Among those with known HIV status, 51.9% (18 648/35 939) were people living with HIV. Note that information on HIV status is not available for the majority of cases.

  • 1 316 cases were reported to be health workers. However, most were exposed in the community and further investigation is ongoing to determine which were due to occupational exposure.

  • Of all reported types of transmission, a sexual encounter was reported most commonly, with 19 140 of 22 844 (83.8%) of all reported transmission events.

  • Of all settings in which cases were likely exposed, the most common was in party setting with sexual contacts, with 4 485 of 6 722 (66.7%) of all reported exposure events.

As of 6 October 2023, the updated case reporting form no longer requires collection of exposure setting as an aspect of the case-based data. While we longer receive this information, we continue to present these data for the historical record.



4.3.1 Demographic Information

Note that the proportions shown below should be interpreted with caution. In some cases, a variable may be more likely to be filled in if the answer is yes than if the answer is no. This is most likely to be true for variables such as HIV status, health worker status, travel history, hospitalization, ICU, and death.

Case profiles
As of 31 Jul 2024
Reported values Unknown or Missing Value
Yes No
Men who have sex with men 30,559 (85.8%) 5,039 (14.2%) 58,112
Persons living with HIV 18,648 (51.9%) 17,291 (48.1%) 57,771
Health worker 1,316 (4.1%) 31,090 (95.9%) 61,304
Travel History 4,110 (15.3%) 22,769 (84.7%) 66,831
Sexual Transmission 19,139 (83.8%) 3,704 (16.2%) 70,867
Hospitalized1 6,074 (11.2%) 48,283 (88.8%) 39,353
ICU 48 (0.3%) 15,157 (99.7%) 78,505
Died 145 (0.3%) 55,835 (99.7%) 37,730
1 May be hospitalized for isolation or medical treatment



4.3.2 Age-sex pyramid



4.3.3 Age-sex pyramid by region

Note different x-axis scales.



4.3.4 Age-sex pyramid (Hospitalized cases)

Note that some cases represented below may be hospitalized for isolation rather than treatment purposes.



4.3.5 Age-sex pyramid (ICU cases)



4.3.6 Sexual behaviour by region



4.3.7 Transmission type

Transmission data were available for 22 844/93 717 (24.4%) of cases.

Transmission can occur during sex via skin-to-skin contact as well as via bodily fluids. While skin-to-skin contact with lesions remains an important transmission route, monkeypox virus has been isolated from semen samples and rectal swabs from confirmed cases. Note that person to person contact excludes known sexual, healthcare-associated, and mother to child transmission.



4.3.8 Exposure settings

Exposure setting data were available for 7 979/93 717 (8.5%) of cases.

Note that multiple exposure settings can be attributed to a single case. Here, differentiation between party settings and large events is determined by size of the event, although there is no formal size threshold to distinguish the two.



4.3.9 Transmission by exposure type

4.4 Case profile (excluding men who have sex with men)

The following outputs apply to cases with sexual behaviour reported as other than men who have sex with men. As above, note that reported sexual behaviour does not necessarily reflect persons who the case has had recent sexual history with nor does it imply sexual activity. Up until this point in time, the multi-country mpox outbreak has been overwhelmingly concentrated in sexual networks of men who have sex with men. For this reason, understanding events in which individuals having other sexual behaviours have acquired mpox is important to monitor potential of sustained spillover into the general population.

  • 79.0% (3 964/5 020) of cases with available data are male; the median age is 33 years (IQR: 27-41).

  • Males between 18-44 years old account for 64.3% of cases.

  • Among those with known HIV status 28.9% (1 128/3 905) were people living with HIV. Note that information on HIV status is not available for the majority of cases.

  • 128 cases were reported to be health workers. However, most were exposed in the community.

  • Of all reported types of transmission, sexual encounter was reported most commonly, with 1 007 of 1 587 (63.5%) of all reported transmission events.

  • Of all settings in which cases were likely exposed, the most common was in households, with 160 of 440 (36.4%) of all likely exposure categories.

4.4.1 Demographic Information

Note that the proportions shown below should be interpreted with caution. In some cases, a variable may be more likely to be filled in if the answer is yes than if the answer is no. This is most likely to be true for variables such as HIV status, health worker status, travel history, hospitalization, ICU, and death.

Case profiles (excluding men who have sex with men)
As of 31 Jul 2024
Reported values Unknown or Missing Value
Yes No
Men who have sex with men 0 5,039 (100.0%) 0
Persons living with HIV 1,128 (28.9%) 2,777 (71.1%) 1,134
Health worker 128 (7.5%) 1,586 (92.5%) 3,325
Travel History 317 (11.6%) 2,421 (88.4%) 2,301
Sexual Transmission 1,007 (63.5%) 580 (36.5%) 3,452
Hospitalized1 414 (16.4%) 2,116 (83.6%) 2,509
ICU 13 (1.0%) 1,226 (99.0%) 3,800
Died 10 (0.4%) 2,768 (99.6%) 2,261
1 May be hospitalized for isolation or medical treatment



4.4.2 Age-sex pyramid excluding men who have sex with men



4.4.3 Transmission type

Transmission data were available for 1 587/5 039 (31.5%) of cases.

Transmission can occur during sex via skin-to-skin contact as well as via bodily fluids. While skin-to-skin contact with lesions remains an important transmission route, monkeypox virus has been isolated from semen samples and rectal swabs from confirmed cases. Note that person to person contact excludes known sexual, healthcare-associated, and mother to child transmission.

All Genders



Male



Female



4.4.4 Exposure settings

Exposure setting data were available for 495/5 039 (9.8%) of cases that were not men who have sex with men.

Note that multiple exposure settings can be attributed to a single case. Here, differentiation between party settings and large events is determined by size of the event, although there is no formal size threshold to distinguish the two.

All Sexes



Male



Female



4.5 Case profile (recent cases)

This section of the report pertains specifically to the most recent six months of the outbreak, and case report forms that were reported in that time period (01 Feb 2024 - 31 Jul 2024).

In the last six months:

  • Of all cases with available information, 99% (996 / 1 010) of cases were male, and 96% (499 / 521) reported being as men who have sex with men.

  • Of all reported types of transmission, a sexual encounter was reported most commonly, with 383 of 408 (93.9%) of all reported transmission events.

4.5.1 Demographic information

Note that the proportions shown below should be interpreted with caution. In some cases, a variable may be more likely to be filled in if the answer is yes than if the answer is no. This is most likely to be true for variables such as HIV status, health worker status, travel history, hospitalization, ICU, and death.

Case profiles
From 01 Feb to 21 Aug 2024
Reported values Unknown or Missing Value
Yes No
Men who have sex with men 499 (95.8%) 22 (4.2%) 571
Persons living with HIV 196 (43.2%) 258 (56.8%) 638
Health worker 14 (4.5%) 298 (95.5%) 780
Travel History 93 (14.4%) 554 (85.6%) 445
Sexual Transmission 383 (93.9%) 25 (6.1%) 684
Hospitalized1 50 (11.4%) 388 (88.6%) 654
ICU 0 201 (100.0%) 891
Died 1 (0.2%) 508 (99.8%) 583
1 May be hospitalized for isolation or medical treatment



4.5.2 Age-sex pyramid, recent cases



4.5.3 Transmission type

Transmission data were available for 408/1 092 (37.4%) of cases.

Transmission can occur during sex via skin-to-skin contact as well as via bodily fluids. While skin-to-skin contact with lesions remains an important transmission route, monkeypox virus has been isolated from semen samples and rectal swabs from confirmed cases. Note that person to person contact excludes known sexual, healthcare-associated, and mother to child transmission.



4.6 Symptomatology

Although most cases in current outbreaks have presented with mild disease symptoms, monkeypox virus (MPXV) may cause severe disease in certain population groups (young children, pregnant women, immunosuppressed persons).

Among the cases who reported at least one symptom, the most common symptom is any rash and is reported in 89% of cases with at least one reported symptom. Note that identifying true denominators for symptomatology is difficult due to a general lack of negative reporting and symptom definitions that may vary between countries’ reporting systems.

A bar chart and table showing symptoms is shown below. Here any rash refers to one or more rash symptoms (systemic, oral, genital, or unknown location), and any lymphadenopathy refers to either general or local lymphadenopathy. Systemic rash included rash on the body, excluding mucosal and genital rash. Symptom information is shown for all cases where information was available reported from January 2022.

4.6.1 Bar chart - Symptoms

All cases

Male cases

Female cases

4.6.2 Table - Symptoms

Summary of symptoms
As of 31 Jul 2024
All Male Female
Any rash 32,397 (88.5%) 31,097 (89.0%) 1,129 (82.0%)
Fever 21,177 (57.9%) 20,278 (58.1%) 724 (52.6%)
Systemic rash 20,030 (54.7%) 19,064 (54.6%) 932 (67.7%)
Genital rash 18,105 (49.5%) 17,574 (50.3%) 392 (28.5%)
Any lymphadenopathy 10,955 (29.9%) 10,664 (30.5%) 230 (16.7%)
Headache 10,536 (28.8%) 9,971 (28.5%) 513 (37.3%)
Muscle ache 9,474 (25.9%) 9,062 (25.9%) 399 (29.0%)
General lymphadenopathy 8,455 (23.1%) 8,246 (23.6%) 149 (10.8%)
Fatigue 6,555 (17.9%) 6,397 (18.3%) 152 (11.0%)
Local lymphadenopathy 5,813 (15.9%) 5,680 (16.3%) 132 (9.6%)
Sore throat 5,544 (15.2%) 5,265 (15.1%) 227 (16.6%)
Rash, unknown location 3,491 (9.5%) 3,466 (9.9%) 22 (1.7%)
Oral rash 2,924 (8.0%) 2,829 (8.1%) 83 (6.0%)
Chills 2,689 (7.3%) 2,534 (7.3%) 121 (8.8%)
Cough 864 (2.4%) 791 (2.3%) 56 (4.1%)
Vomiting 776 (2.1%) 721 (2.1%) 52 (3.8%)
Lymphadenopathy, location unknown 472 (1.3%) 458 (1.3%) 14 (1.0%)
Anogenital pain and/or bleeding 382 (1.0%) 376 (1.1%) 6 (0.4%)
Asymptomatic 284 (0.8%) 259 (0.7%) 18 (1.3%)
Other 254 (0.7%) 249 (0.7%) 5 (0.4%)
Conjunctivitis 205 (0.6%) 189 (0.5%) 14 (1.0%)
Diarrhea 128 (0.3%) 106 (0.3%) 2 (0.1%)
Genital oedema 45 (0.1%) 44 (0.1%) 0

 


5 Genomic epidemiology

Sequence alignment and visualisation of sequences available on NCBI Genbank is regularly carried out by Nextstrain, using both historical sequences and sequences associated with the 2022-24 multi-country mpox outbreak. On 12 August 2022, after reaching consensus among scientists from different fields and from different countries, WHO decided to rename the MPXV clades from the Congo Basin clade as Clade one (I) and the West African clade as Clade two (II). Additionally, it was agreed that the Clade II consists of two subclades, Clade IIa and Clade IIb.

The following visualisations are derived from Nextstrain alignments of Genbank data under the mpxv dataset. Further details on methods and interactive visualisation can be found on the Nextclade website and GitHub. Phylogenetic trees were visualised in R with the ggtree and treeio packages. As of 01 Aug 2024, a total of 314 sequences were visualised. Note that these data do not include data submitted to GISAID, the other major platform for sharing mpox genomic data.

At present, all sequences in the ongoing 2022-24 global mpox outbreak are associated with Clade IIb. Among these, the vast majority have been associated with the B.1 lineage of Clade IIb. Despite this, a number of sequences have been associated with the related A.2 lineage. Currently, the similarities between the sequences uploaded from different areas of the world suggest that the ongoing outbreak does not involve multiple zoonotic spillover events, and transmission is sustained through human-to-human transmission. In order to understand when sustained human to human transmission started, it is critical to analyse the diversity of sequences from the period prior to the current outbreak in countries that experienced continuous circulation of monkeypox virus.

5.1 Phylogeny focused on 2022-24 outbreak

Click on image to expand

5.2 Phylogeny prior to 2022-24 outbreak

Click on image to expand

 


6 Literature summary & epidemic parameters

In order to promote a better understanding of the dynamics of the mpox outbreak and to support forecasting work, in 2022, WHO undertook an effort to extract epidemiological parameters (incubation period, serival interval and generation interval) from the literature. The initial literature screening was performed and maintained by the Public Health Agency of Canada (PHAC). The overall search strategy was as follows:

  • Inclusion criteria: monkeypox and monkeypox virus
  • Study design:
    • Any study design including primary and secondary studies (both animal and human)
    • Guidelines and commentaries are not excluded but are not searched systematically.
  • Publication language: no restriction for peer-reviewed articles, grey literature is focused on English
  • Publication date: from April 14, 2022 – January 19, 2023
  • Bibliographic databases and other sources searched:
    • PubMed Scopus
    • Pre-print servers: Europe PMC, arXiv and SSRN
    • WHO, PHAC, CDC, ECDC, UKHSA

The tables below provide an overview of the most relevant estimates for incubation period and generation interval extracted from the literature where the following criteria are met:

  • Studies with a sample size greater than 5
  • Clear estimate of the specific parameter

The epidemic parameter tables are no longer updated, as the literature screening is no longer carried out.

6.1 Parameters

Incubation Period
As of 19 Jan 2023
Reference N Mean1 95% CrI (mean)1 95% CI (mean)1 SD1 Median1 95% CrI (median)1 IQR1 Range1 Distribution
Miura et al. [1] 18 8.5 6.6 - 10.9 - - - - - - Log-normal
Charniga et al. [2] 40 7.6 6.2 - 9.7 - 1.8 6.4 5.1 - 7.9 - - Log-normal
Rodríguez et al. [3] 45 - - - - - - - - -
Thornhill et al. [4] 23 - - - - 7.0 - - 3 - 20 -
Català et al. [5] 77 - - - - 6.0 - - 4 - 9 -
Tarín-Vicente et al. [6] 144 - - - - 7.0 - 5 - 10 1 - 19 -
Guzzetta et al. [7] 30 9.1 - 6.5 - 10.9 - - - - - Gamma
Mailhe et al. [8] 112 - - - - 6.0 - 3 - 8 - -
Moschese et al. [9] 16 - - - - 11.0 - 11 - 16 - -
Gomez-Garberi et al. [10] 14 - - - - 13.0 - - 3 - 30 -
O'Laughlin et al. [11] 527 7.0 - - - - - 4 - 9 - -
Angelo et al. [12] 78 - - - - 8.0 - 5 - 11 2 - 40 -
Madewell et al. [14] 35 5.6 4.3 - 7.8 - - - - - - -
Ward et al. [15] 54 7.8 6.6 - 9.2 - - - - - - Weibull
Besombes et al. [16] 29 - - - - 7.0 - 1 - 13 0 - 17 -
Kröger et al. [17] 209 8.2 - - 4.7 - - - - Log-normal
Source: PHAC
1 Units are in days




Serial Interval
As of 19 Jan 2023
Reference N Mean1 95% CrI (mean)1 SD1 Median1 95% CrI (median)1 Distribution
Guo et al. [13] 21 5.6 1.7 - 10.4 1.5 5.5 1.4 - 10.4 -
Madewell et al. [14] 57 8.5 7.3 - 9.9 - - - Gamma
Ward et al. [15] 79 9.5 7.4 - 12.3 - - - Gamma
Miura et al. [18] 34 9.4 - 6.2 - - Normal
Source: PHAC
1 Units are in days




Generation Interval
As of 19 Jan 2023
Reference N Mean1 95% CrI1 Distribution
Guzzetta et al. [7] 16 12.5 7.5 - 17.3 Gamma
Source: PHAC
1 Units are in days


6.2 Bibliography

  1. The incubation period for monkeypox cases confirmed in the Netherlands, May 2022 ( 658) medRxiv . Miura, Fuminari, van Ewijk, Catharina Else, Backer, Jantien A., Xiridou, Maria, Franz, Eelco, de Coul, Eline Op, Brandwagt, Diederik, van Cleef, Brigitte, van Rijckevorsel, Gini, Swaan, Corien, van den Hof, Susan, Wallinga, Jacco. #volume# (2022): 2022.06.09.22276068–> 10.1101/2022.06.09.22276068 ; http://medrxiv.org/content/early/2022/06/13/2022.06.09.22276068.abstract

  2. Estimating the incubation period of monkeypox virus during the 2022 multi-national outbreak ( 722) medRxiv . Charniga, Kelly, Masters, Nina B., Slayton, Rachel B., Gosdin, Lucas, Minhaj, Faisal S., Philpott, David, Smith, Dallas, Gearhart, Shannon, Alvarado-Ramy, Francisco, Brown, Clive, Waltenburg, Michelle A., Hughes, Christine M., Nakazawa, Yoshinori. #volume# (2022): 2022.06.22.22276713–> 10.1101/2022.06.22.22276713 ; http://medrxiv.org/content/early/2022/06/23/2022.06.22.22276713.abstract

  3. Epidemiologic Features and Control Measures during Monkeypox Outbreak, Spain, June 2022 ( 888) Emerg Infect Dis . Rodríguez, B. S., Herrador, B. R. G., Franco, A. D., Fariñas, M. P. S., Del Amo Valero, J., Llorente, A. H. A., de Agreda, Jpap, Malonda, R. C., Castrillejo, D., Chirlaque López, M. D., Chong, E. J., Balbuena, S. F., García, V. G., García-Cenoz, M., Hernández, L. G., Montalbán, E. G., Carril, F. G., Cortijo, T. G., Bueno, S. J., Sánchez, A. L., Linares Dópido, J. A., Lorusso, N., Martins, M. M., Martínez Ochoa, E. M., Mateo, A. M., Peña, J. M., Antón, A. I. N., Otero Barrós, M. T., Martinez, Mdcp, Jiménez, P. P., Martín, O. P., Rivas Pérez, A. I., García, M. S., Soria, F. S., Sierra Moros, M. J.. 28,2022/07/13 (2022): #pages#–> 10.3201/eid2809.221051 ; https://wwwnc.cdc.gov/eid/article/28/9/22-1051_article

  4. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 ( 933) N Engl J Med . Thornhill, J. P., Barkati, S., Walmsley, S., Rockstroh, J., Antinori, A., Harrison, L. B., Palich, R., Nori, A., Reeves, I., Habibi, M. S., Apea, V., Boesecke, C., Vandekerckhove, L., Yakubovsky, M., Sendagorta, E., Blanco, J. L., Florence, E., Moschese, D., Maltez, F. M., Goorhuis, A., Pourcher, V., Migaud, P., Noe, S., Pintado, C., Maggi, F., Hansen, A. E., Hoffmann, C., Lezama, J. I., Mussini, C., Cattelan, A., Makofane, K., Tan, D., Nozza, S., Nemeth, J., Klein, M. B., Orkin, C. M.. 2022/07/23 (2022): #pages#–> 10.1056/NEJMoa2207323 ; #URL#

  5. Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases ( 1008) Br J Dermatol . Català, A., Clavo Escribano, P., Riera, J., Martín-Ezquerra, G., Fernandez-Gonzalez, P., Revelles Peñas, L., Simón Gozalbo, A., Rodríguez-Cuadrado, F. J., Guilera Castells, V., De la Torre Gomar, F. J., Comunión Artieda, A., Fuertes de Vega, L., Blanco, J. L., Puig, S., García Miñarro Á, M., Fiz Benito, E., Muñoz-Santos, C., Repiso-Jiménez, J. B., Ceballos-Rodriguez, C., García Rodríguez, V., Castaño Fernández, J. L., Sánchez-Gutiérrez, I., Calvo López, R., Berna-Rico, E., de Nicolás-Ruanes, B., Corella Vicente, F., Tarín Vicente, E. J., Fernández de la Fuente, L., Riera-Martí, N., Descalzo-Gallego, M., Grau-Perez, M., García-Doval, I., Fuertes, I.. 2022/08/03 (2022): #pages#–> 10.1111/bjd.21790 ; #URL#

  6. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study ( 1074) Lancet . Tarín-Vicente, E. J., Alemany, A., Agud-Dios, M., Ubals, M., Suñer, C., Antón, A., Arando, M., Arroyo-Andrés, J., Calderón-Lozano, L., Casañ, C., Cabrera, J. M., Coll, P., Descalzo, V., Folgueira, M. D., García-Pérez, J. N., Gil-Cruz, E., González-Rodríguez, B., Gutiérrez-Collar, C., Hernández-Rodríguez, Á., López-Roa, P., de Los Ángeles Meléndez, M., Montero-Menárguez, J., Muñoz-Gallego, I., Palencia-Pérez, S. I., Paredes, R., Pérez-Rivilla, A., Piñana, M., Prat, N., Ramirez, A., Rivero, Á., Rubio-Muñiz, C. A., Vall, M., Acosta-Velásquez, K. S., Wang, A., Galván-Casas, C., Marks, M., Ortiz-Romero, P., Mitjà, O.. 2022/08/12 (2022): #pages#–> 10.1016/s0140-6736(22)01436-2 ; #URL#

  7. Early Estimates of Monkeypox Incubation Period, Generation Time, and Reproduction Number, Italy, May-June 2022 ( 1189) Emerg Infect Dis . Guzzetta, G., Mammone, A., Ferraro, F., Caraglia, A., Rapiti, A., Marziano, V., Poletti, P., Cereda, D., Vairo, F., Mattei, G., Maraglino, F., Rezza, G., Merler, S.. 28,2022/08/23 (2022): #pages#–> 10.3201/eid2810.221126 ; https://wwwnc.cdc.gov/eid/article/28/10/22-1126_article

  8. Clinical characteristics of ambulatory and hospitalised patients with monkeypox virus infection: an observational cohort study ( 1238) Clin Microbiol Infect . Mailhe, M., Beaumont, A. L., Thy, M., Le Pluart, D., Perrineau, S., Houhou-Fidouh, N., Deconinck, L., Bertin, C., Ferré, V. M., Cortier, M., C.,De La Porte Des Vaux,, Phung, B. C., Mollo, B., Cresta, M., Bouscarat, F., Choquet, C., Descamps, D., Ghosn, J., Lescure, F. X., Yazdanpanah, Y., Joly, V., Peiffer-Smadja, N.. 2022/08/27 (2022): #pages#–> 10.1016/j.cmi.2022.08.012 ; #URL#

  9. Natural history of Human Monkeypox in individuals attending a sexual health clinic in Milan, Italy ( 1262) J Infect . Moschese, D., Pozza, G., Giacomelli, A., Mileto, D., Cossu, M. V., Beltrami, M., Rizzo, A., Gismondo, M. R., Rizzardini, G., Antinori, S.. 2022/08/26 (2022): #pages#–> 10.1016/j.jinf.2022.08.019 ; #URL#

  10. Genitourinary Lesions Due to Monkeypox ( 1440) Eur Urol . Gomez-Garberi, M., Sarrio-Sanz, P., Martinez-Cayuelas, L., Delgado-Sanchez, E., Bernabeu-Cabezas, S., Peris-Garcia, J., Sanchez-Caballero, L., Nakdali-Kassab, B., Egea-Sancho, C., Olarte-Barragan, E., Ortiz-Gorraiz, M.. 2022/09/13 (2022): #pages#–> 10.1016/j.eururo.2022.08.034 ; #URL#

  11. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022 ( 1486) MMWR Morb Mortal Wkly Rep . O’Laughlin, K., Tobolowsky, F. A., Elmor, R., Overton, R., O’Connor, S. M., Damon, I. K., Petersen, B. W., Rao, A. K., Chatham-Stephens, K., Yu, P., Yu, Y.. 71,2022/09/16 (2022): 1190–> 10.15585/mmwr.mm7137e1 ; #URL#

  12. Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study ( 1748) Lancet Infect Dis . Angelo, K. M., Smith, T., Camprubí-Ferrer, D., Balerdi-Sarasola, L., Díaz Menéndez, M., Servera-Negre, G., Barkati, S., Duvignaud, A., Huber, K. L. B., Chakravarti, A., Bottieau, E., Greenaway, C., Grobusch, M. P., Mendes Pedro, D., Asgeirsson, H., Popescu, C. P., Martin, C., Licitra, C., de Frey, A., Schwartz, E., Beadsworth, M., Lloveras, S., Larsen, C. S., Guagliardo, S. A. J., Whitehill, F., Huits, R., Hamer, D. H., Kozarsky, P., Libman, M.. 2022/10/11 (2022): #pages#–> 10.1016/s1473-3099(22)00651-x ; #URL#

  13. Estimation of the serial interval of monkeypox during the early outbreak in 2022 ( 1895) J Med Virol . Guo, Z., Zhao, S., Sun, S., He, D., Chong, K. C., Yeoh, E. K.. 2022/10/23 (2022): #pages#–> 10.1002/jmv.28248 ; #URL#

  14. Serial interval and incubation period estimates of monkeypox virus infection in 12 U.S. jurisdictions, May - August 2022 ( 2007) medRxiv . Madewell, Zachary, Charniga, Kelly, Masters, Nina, Asher, Jason, Fahrenwald, Lily, Still, William, Chen, Judy, Kipperman, Naama, Bui, David, Shea, Meghan, Saathoff-Huber, Lori, Johnson, Shannon, Harbi, Khalil, Berns, Abby, Perez, Taidy, Gateley, Emily, Spicknall, Ian, Nakazawa, Yoshinori, Gift, Thomas. #volume# (2022): #pages#–> 10.1101/2022.10.26.22281516 ; http://europepmc.org/abstract/PPR/PPR564657 https://doi.org/10.1101/2022.10.26.22281516

  15. Transmission dynamics of monkeypox in the United Kingdom: contact tracing study ( 2069) Bmj . Ward, T., Christie, R., Paton, R. S., Cumming, F., Overton, C. E.. 379,2022/11/03 (2022): e073153–> 10.1136/bmj-2022-073153 ; #URL#

  16. National Monkeypox Surveillance, Central African Republic, 2001-2021 ( 2104) Emerg Infect Dis . Besombes, C., Mbrenga, F., Schaeffer, L., Malaka, C., Gonofio, E., Landier, J., Vickos, U., Konamna, X., Selekon, B., Dankpea, J. N., Von Platen, C., Houndjahoue, F. G., Ouaïmon, D. S., Hassanin, A., Berthet, N., Manuguerra, J. C., Gessain, A., Fontanet, A., Yandoko, E. N.. 28,2022/11/04 (2022): #pages#–> 10.3201/eid2812.220897 ; https://wwwnc.cdc.gov/eid/article/28/12/22-0897_article

  17. Monkeypox outbreak 2022 – an overview of all cases reported to the Cologne Health Department ( 2181) Research Square . Kröger, Sophia Toya, Lehmann, Max Christian, Treutlein, Melanie, Fiethe, Achim, Kossow, Annelene, Küfer-Weiß, Annika, Nießen, Johannes, Grüne, Barbara. #volume# (2022): #pages#–> 10.21203/rs.3.rs-2251751/v1 ; http://europepmc.org/abstract/PPR/PPR570380 https://doi.org/10.21203/rs.3.rs-2251751/v1

  18. Time scales of human monkeypox transmission in the Netherlands ( 2405) medRxiv . Miura, Fuminari, Backer, Jantien, van Rijckevorsel, Gini, Bavalia, Roisin, Raven, Stijn, Petrignani, Mariska, Ainslie, Kylie E. C., Wallinga, Jacco. #volume# (2022): #pages#–> 10.1101/2022.12.03.22283056 ; http://europepmc.org/abstract/PPR/PPR579534 https://doi.org/10.1101/2022.12.03.22283056

 


7 Archive: 2022-23 acute outbreak phase

With reporting frequencies declining, and with new WHO guidance specifying monthly reporting intervals, it is no longer reliable to present cases by week of report. However, in an effort to retain data availability, we present a record of the acute phase of the 2022-2024 outbreak by reporting week. While the end of the acute phase of the outbreak is not explicitly defined, we present data from 1 January 2022 to 14 April 2023, which corresponds to the week when mpox was no longer considered to be a public health emergency of international concern.

Regional trends are shown below:

7.1 Epidemic curve by date of notification (cases)

Epidemic curve shown by month for cases reported up to 14 April 2023.

7.2 Epidemic curve by date of notification (deaths)

Epidemic curve shown by month for deaths reported up to 14 April 2023.

7.3 Epidemic curve by WHO region (cases)

Epidemic curve shown by month for cases reported up to 14 April 2023. Note different y-axis scales.

 


8 Disclaimers

8.1 Data Overview and Visualizations

The WHO 2022-24 mpox global trends report aims to provide frequently updated data visualizations. Caution must be taken when interpreting all data presented, and differences between information products published by WHO, national public health authorities, and other sources using different inclusion criteria and different data cut-off times are to be expected. While steps are taken to ensure accuracy and reliability, all data are subject to continuous verification and change. All counts are subject to variations in case detection, definitions, laboratory testing, and reporting strategies between countries, states and territories.

Data are compiled and shared with WHO by national public health authorities. Data compilation and submission to WHO Headquarters is done by the WHO Regional Offices and WHO Country Offices.

WHO makes no warranties or representations regarding the contents, appearance, completeness, technical specifications, or accuracy of the report. WHO disclaims all responsibility relating to, and shall not be liable for, any use of the report, the results of such use, or the reliance thereon.

WHO reserves the right to make updates and changes to the report without notice, and accepts no liability for any errors or omissions in this regard.

The user of the report is responsible for the interpretation and use of the analysis and outputs performed by the report. The submission of content to the report does not imply WHO’s approval or endorsement of that content, or that the content is appropriate for any purpose or meets any established standard or requirement

Any designations employed or presentation by the user in its use of the app, including tables and maps, do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries.

All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).

9 Acknowledgements

We gratefully acknowledge the input of national public health staff involved in surveillance activities and data submission to WHO, the WHO regional and country offices for the timely compilation of data, and the European Centre for Disease Prevention and Control (ECDC) for the provision of surveillance data collected via the TESSy platform, as well as external partners who contributed additional insights and contextual information on the data.